Follow
Nathanael Gray
Nathanael Gray
Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
Verified email at dfci.harvard.edu
Title
Cited by
Cited by
Year
Targeting cancer with small molecule kinase inhibitors
J Zhang, PL Yang, NS Gray
Nature reviews cancer 9 (1), 28-39, 2009
31912009
Systematic identification of genomic markers of drug sensitivity in cancer cells
MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ...
Nature 483 (7391), 570-575, 2012
24722012
A next generation connectivity map: L1000 platform and the first 1,000,000 profiles
A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ...
Cell 171 (6), 1437-1452. e17, 2017
23312017
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1
CC Thoreen, SA Kang, JW Chang, Q Liu, J Zhang, Y Gao, LJ Reichling, ...
Journal of Biological Chemistry 284 (12), 8023-8032, 2009
19772009
A landscape of pharmacogenomic interactions in cancer
F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ...
Cell 166 (3), 740-754, 2016
15832016
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
TR Peterson, M Laplante, CC Thoreen, Y Sancak, SA Kang, WM Kuehl, ...
Cell 137 (5), 873-886, 2009
15232009
A unifying model for mTORC1-mediated regulation of mRNA translation
CC Thoreen, L Chantranupong, HR Keys, T Wang, NS Gray, DM Sabatini
Nature 485 (7396), 109-113, 2012
15162012
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu, NS Gray
Nature chemical biology 2 (7), 358-364, 2006
12912006
A chemical switch for inhibitor-sensitive alleles of any protein kinase
AC Bishop, JA Ubersax, DT Petsch, DP Matheos, NS Gray, J Blethrow, ...
nature 407 (6802), 395-401, 2000
12302000
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
JP Koivunen, C Mermel, K Zejnullahu, C Murphy, E Lifshits, AJ Holmes, ...
Clinical cancer research 14 (13), 4275-4283, 2008
11962008
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling
PP Hsu, SA Kang, J Rameseder, Y Zhang, KA Ottina, D Lim, TR Peterson, ...
science 332 (6035), 1317-1322, 2011
11742011
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti, AB Cortot, ...
Nature 462 (7276), 1070-1074, 2009
11442009
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
NS Gray, L Wodicka, AMWH Thunnissen, TC Norman, S Kwon, ...
Science 281 (5376), 533-538, 1998
11361998
Activating mutations in ALK provide a therapeutic target in neuroblastoma
RE George, T Sanda, M Hanna, S Fröhling, WL Ii, J Zhang, Y Ahn, ...
Nature 455 (7215), 975-978, 2008
9822008
Systematic identification of culture conditions for induction and maintenance of naive human pluripotency
TW Theunissen, BE Powell, H Wang, M Mitalipova, DA Faddah, J Reddy, ...
Cell stem cell 15 (4), 471-487, 2014
8912014
The promise and peril of chemical probes
CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ...
Nature chemical biology 11 (8), 536-541, 2015
8012015
YY1 is a structural regulator of enhancer-promoter loops
AS Weintraub, CH Li, AV Zamudio, AA Sigova, NM Hannett, DS Day, ...
Cell 171 (7), 1573-1588. e28, 2017
7932017
Kinase inhibitors: the road ahead
FM Ferguson, NS Gray
Nature reviews Drug discovery 17 (5), 353-377, 2018
7832018
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
N Kwiatkowski, T Zhang, PB Rahl, BJ Abraham, J Reddy, SB Ficarro, ...
Nature 511 (7511), 616-620, 2014
7802014
MEK1 mutations confer resistance to MEK and B-RAF inhibition
CM Emery, KG Vijayendran, MC Zipser, AM Sawyer, L Niu, JJ Kim, ...
Proceedings of the National Academy of Sciences 106 (48), 20411-20416, 2009
7502009
The system can't perform the operation now. Try again later.
Articles 1–20